基线SUVmax未能预测GALLIUM研究中滤泡性淋巴瘤的组织学转化
该研究基于3期GALLIUM试验549例高肿瘤负荷初治滤泡性淋巴瘤患者的回顾性分析,评估基线PET的SUVmax与组织学转化风险的关系。中位随访59个月,15例(2.7%)发生活检证实的组织学转化。SUVmax>10或>20均未预测组织学转化,提示不应仅基于SUVmax决定治疗前是否重新活检。
要点
- 高肿瘤负荷滤泡性淋巴瘤基线SUVmax>10或>20均未预测组织学转化风险。
- 549例中仅15例(2.7%)发生活检证实的组织学转化,中位随访59个月。
- 不建议仅依据基线SUVmax决定治疗前是否对病灶重新活检以排除转化。
核心结论
- 在GALLIUM研究中,基线SUVmax和bSUVrange均未能预测滤泡性淋巴瘤的组织学转化。
研究设计与样本
- 3期GALLIUM研究(NCT01332968)的回顾性分析,纳入549例初治高肿瘤负荷1-3a级滤泡性淋巴瘤患者,接受obinutuzumab或rituximab为基础的化疗诱导。
主要发现
- 549例中15例(2.7%)发生活检证实的组织学转化,中位随访59个月。
- 超过65%的患者基线SUVmax>10,其中3.3%发生组织学转化;基线SUVmax>20的74例中仅1例(1.4%)发生转化。
- 组织学转化组与未转化组的中位基线SUVmax分别为12.4(范围8.1-28.0)和11.8(范围3.1-64.4)。
- 组织学转化组与未转化组的中位bSUVrange分别为8.0(范围1.1-23.9)和7.1(范围0.0-59.8)。
- 基线SUVmax与组织学转化之间无时间关系。
关键数值与推荐
- 采用SUVmax>10和>20两个 cutoff 值评估基线SUVmax与组织学转化风险的关系。
临床怎么用
- 对高肿瘤负荷滤泡性淋巴瘤患者,不应仅基于基线SUVmax决定治疗前是否重新活检以排除组织学转化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A minority of patients with follicular lymphoma (FL) undergo histological transformation (HT). This retrospective analysis of 549 patients from the phase 3 GALLIUM study (NCT01332968) assessed the relationship between maximum standardized uptake value (SUVmax) at baseline on positron emission tomography (PET) and HT risk. Previously untreated patients with high tumor burden grade 1-3a FL received obinutuzumab- or rituximab-based chemotherapy induction. The relationship between baseline SUVmax (bSUVmax) and HT risk was assessed using cutoff values for SUVmax >10 and >20. Overall, 15 of 549 (2.7%) patients with baseline PET scans experienced biopsy-confirmed HT (median follow-up, 59 months). More than 65% of patients had bSUVmax > 10, with 3.3% of these experiencing HT. Only 1 of 74 (1.4%) patients with bSUVmax > 20 underwent HT. Median bSUVmax in patients with HT vs without HT was 12.4 (range, 8.1-28.0) vs 11.8 (range, 3.1-64.4), respectively; median bSUVrange (the difference between bSUVmax of the most and least 18F-fluorodeoxyglucose-avid lymphoma sites) was 8.0 (range, 1.1-23.9) vs 7.1 (range, 0.0-59.8), respectively. There was no temporal relationship between bSUVmax and HT. Neither bSUVmax nor bSUVrange predicted HT in GALLIUM, suggesting that there may be little benefit in rebiopsy of lesions to exclude HT based on SUVmax alone before initiating therapy in patients with high tumor burden FL.
引用
- Mir F, Barrington SF, Brown H, et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood. 2020. PMID: 31961926. doi:10.1182/blood.2019001091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。